Mexiletine

Mexiletine

Clinical data
Pregnancy category	AU: B1 US: C (Risk not ruled out)
Routes of administration	Oral, IV
ATC code	C01BB02 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	90%
Protein binding	50-60%
Metabolism	Hepatic (CYP2D6 and 1A2- mediated)
Elimination half-life	10-12 hours
Excretion	Renal (10%)
Identifiers
IUPAC name 1-(2,6-dimethylphenoxy)propan-2-amine
CAS Number	31828-71-4
PubChem CID	4178
DrugBank	APRD00242
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H17NO
Molar mass	179.259 g/mol

WikiDoc Resources for Mexiletine
Articles
Most recent articles on Mexiletine Most cited articles on Mexiletine Review articles on Mexiletine Articles on Mexiletine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mexiletine Images of Mexiletine Photos of Mexiletine Podcasts & MP3s on Mexiletine Videos on Mexiletine
Evidence Based Medicine
Cochrane Collaboration on Mexiletine Bandolier on Mexiletine TRIP on Mexiletine
Clinical Trials
Ongoing Trials on Mexiletine at Clinical Trials.gov Trial results on Mexiletine Clinical Trials on Mexiletine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mexiletine NICE Guidance on Mexiletine NHS PRODIGY Guidance FDA on Mexiletine CDC on Mexiletine
Books
Books on Mexiletine
News
Mexiletine in the news Be alerted to news on Mexiletine News trends on Mexiletine
Commentary
Blogs on Mexiletine
Definitions
Definitions of Mexiletine
Patient Resources / Community
Patient resources on Mexiletine Discussion groups on Mexiletine Patient Handouts on Mexiletine Directions to Hospitals Treating Mexiletine Risk calculators and risk factors for Mexiletine
Healthcare Provider Resources
Symptoms of Mexiletine Causes & Risk Factors for Mexiletine Diagnostic studies for Mexiletine Treatment of Mexiletine
Continuing Medical Education (CME)
CME Programs on Mexiletine
International
Mexiletine en Espanol Mexiletine en Francais
Business
Mexiletine in the Marketplace Patents on Mexiletine
Experimental / Informatics
List of terms related to Mexiletine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Mexiletine (INN, sold under the trade name Mexitil®) belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat arrhythmias within the heart - or seriously irregular heartbeats. It slows nerve impulses in the heart and makes the heart tissue less sensitive. Dizziness, heartburn, nausea, nervousness, trembling, unsteadiness are common side effects. It is available in injection and capsule form.

Class IB antiarrhythmics decrease action potential duration by shortening the repolarization phase. This is achieved by blocking sodium channels[3].

Mexiletine may also be of use in patients experiencing refractory pain. (Sweetman, 2002) and is also effective for treating muscle stiffness resulting from myotonia congenita (Thomsen disease)

External links

• MedlinePlus Drug Information: Mexiletine

References

• Peck T (2004). Pharmacology for Anaesthesia and Intensive Care (2nd ed. ed.). Cambridge University Press. ISBN 0-521-68794-2. CS1 maint: Extra text (link)
• Sweetman S (ed.) (2002). Martindale: The complete drug reference (33rd ed. ed.). London: Pharmaceutical Press. ISBN 0-85369-499-0.CS1 maint: Extra text: authors list (link) CS1 maint: Extra text (link)

Template:Antiarrhythmic agents

Template:WikiDoc Sources